Weight loss surgery plus GLP-1 drug for obesity and diabetes
Part of Hormones & metabolism clinical trials.
This trial tests whether adding a GLP-1 receptor agonist (a medication that helps control blood sugar and appetite) after weight loss surgery improves outcomes for people with severe obesity and related health problems like type 2 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- Your body mass index (BMI) is 35 or higher
- You have metabolic syndrome or type 2 diabetes
- You are about to have your first sleeve gastrectomy surgery
- You have not taken a GLP-1 drug in the last 6 months
- You have not had any previous weight loss surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a GLP-1 medication (a type of diabetes and weight-loss drug) after weight-loss surgery helps patients with obesity and related health conditions like diabetes. Researchers want to see if combining surgery with this medicine works better than surgery alone.
This study tests if adding a GLP-1 medication to weight-loss surgery helps people with obesity and related conditions like diabetes. It may improve weight loss and blood sugar control more than surgery alone.
This study tests whether bariatric (weight-loss) surgery can improve blood sugar control in people with obesity and either prediabetes or type 2 diabetes. You may be enrolled in one of these glucose groups, and the researchers will monitor changes before and after surgery.
This trial tests a type of weight-loss surgery (called metabolic surgery) to see if it helps people with type 2 diabetes achieve better blood sugar control. It's for people who have struggled to manage their diabetes with standard treatments and have a BMI between 30 and 35.
This trial studies bariatric (weight-loss) surgery and how well it helps people reach and keep a healthier weight. You may qualify if you have severe obesity and have not been able to maintain weight loss with other attempts, and if you can safely follow the study plan.
This early-phase trial tests whether an SGLT2 drug can reduce inflammation in belly fat and improve blood vessel function. It may help people with metabolic syndrome prepare for (and potentially benefit around) planned gastric bypass or sleeve surgery.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.